Publications
Issues
Promise Newsletter - Summer 2009
Hope grows in the Summer 2009 issue of Promise, a newsletter of the Development Office at M. D. Anderson, with an update on the George and Barbara Bush Endowment for Innovative Cancer Research, plus timely fundraising efforts, research highlights, awe-inspiring donor stories, newsworthy awards and more. Check out new features iPromise and Survivors Say, and, in Among Friends, read about an Atlanta man’s personal battle against lung cancer.
Promise Newsletter - Spring 2009
The BATTLE Toward Personalized Lung Cancer Therapy - More people die from lung cancer than from breast, prostate and colon cancers combined.M. D. Anderson’s Lung Cancer Research Program is striving to change those statistics.
Promise Newsletter - Fall 2008
A Helping Hand - At the School of Health Sciences, Scholarships Address a Critical Need
Promise Newsletter - Summer 2008
Targeting Cancer Before It Starts - Dan L. Duncan Family Supports Prevention Program with $35 Million Gift
Promise Newsletter - Spring 2008
Banking on Hope - Cord Blood Collection Expands Options for Stem Cell Transplant Candidates.
Promise Newsletter - Fall 2007
Philanthropy: The Gift that Keeps on Giving - Harrison Elias is a tall, lanky eighth-grader who looks forward to his last year of middle school, enjoys football and basketball and plays a mean drum solo - traits of the typcial 14-year-old, one might say.
But Harrison is far from typical.
Promise Newsletter - Summer 2007
CABIR Center for Advanced Biomedical Imaging Research - Long before they are large enough to be detected by the most sensitive current imaging techniques, tiny tumors weave a web of new blood vessels to nourish their growth. Juri Gelovani, M.D., Ph.D., chair of M. D. Anderson’s Department of Experimental Diagnostic Imaging, believes researchers can turn this blood supply against tumors to betray their existence before they can be imaged directly.
Promise Newsletter - Spring 2007
Center Focuses on Personalized Cancer Therapies - M. D. Anderson’s Center for Targeted Therapy (CTT) is in the thick of two great changes in cancer care: developing drug therapies that prey on the molecular vulnerabilities of cancer while largely sparing normal tissue, and personalizing cancer treatments to individual patients. “It’s an amazingly exciting time to be doing what we are doing now,” says Garth Powis, D.Phil., director of the CTT and chair of the Department of Experimental Therapeutics.